Skip to main content

Table 6 Placebo product detection in vaginal swabs of the 135 Study

From: Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies

Time HEC gel Vaginal film Vaginal insert
HEC FTIR Glycerin FTIR Sorbitol FTIR
0 0 0 0 0 0 0
15 min 100 100 100 100 100 100
6–12 h 100 100 90 100 90 80
24 h 90 50 70 90 80 20
48 h 40 50 40 70 70 40
72 h 22 50 20 40 30 40
96 h 20 60 10 30 60 50
120 h 10 50 0 20 30 50
144 h 10 50 0 10 10 40
With semen exposure
 0 10 0 0 0 0 0
 15 min 100 100 100 100 90 90
 8–16 ha 100 70 70 90 90 100
 24 h 50 70 40 100 60 50
 48 h 20 30 30 80 40 30
 72 h 30 40 20 50 30 30
 96 h 20 10 0 30 10 20
 120 h 20 10 0 40 0 30
 144 h 0 20 0 40 0 22
  1. Numbers represent the percent of total vaginal swabs containing detectable placebo product, n = 9–10 swabs per time point
  2. aSwab obtained after vaginal intercourse